Molecular profile of driver genes in lung adenocarcinomas of Brazilian patients who have never smoked: implications for targeted therapies.

Autor:	Cavagna RO; Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, Brazil., Escremim de Paula F; Molecular Diagnostic Laboratory, Barretos Cancer Hospital, Barretos, Brazil., Berardinelli GN; Molecular Diagnostic Laboratory, Barretos Cancer Hospital, Barretos, Brazil., Bonatelli M; Molecular Diagnostic Laboratory, Barretos Cancer Hospital, Barretos, Brazil., Santana I; Department of Pathology, Barretos Cancer Hospital, Barretos, Brazil., Albino da Silva EC; Department of Pathology, Barretos Cancer Hospital, Barretos, Brazil., Teixeira GR; Department of Pathology, Barretos Cancer Hospital, Barretos, Brazil.; Barretos School of Health Sciences, Dr. Paulo Prata - FACISB, Barretos, Brazil., Zaniolo BG; Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, Brazil.; Barretos School of Health Sciences, Dr. Paulo Prata - FACISB, Barretos, Brazil., Mourão Dias J; Department of Medical Oncology, Barretos Cancer Hospital, Barretos, Brazil., Ferreira da Silva FA; Department of Medical Oncology, Barretos Cancer Hospital, Barretos, Brazil., Baston Silva CE; Department of Medical Oncology, Barretos Cancer Hospital, Barretos, Brazil., Guimarães MGB; Department of Medical Oncology, Barretos Cancer Hospital, Barretos, Brazil., Barone CP; Department of Medical Oncology, Barretos Cancer Hospital, Barretos, Brazil., Jacinto AA; Deparment of Radiation Therapy, Barretos Cancer Hospital, Barretos, Brazil., Noleto da Nóbrega Oliveira RE; Deparment of Thoracic Surgery, Barretos Cancer Hospital, Barretos, Brazil., Miziara JE; Deparment of Thoracic Surgery, Barretos Cancer Hospital, Barretos, Brazil., De Marchi P; Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, Brazil.; Oncoclinicas, Rio de Janeiro, Brazil., Molina-Vila MA; Laboratory of Oncology/Pangaea Oncology, Dexeus University Hospital, Barcelona, Spain., Leal LF; Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, Brazil.; Barretos School of Health Sciences, Dr. Paulo Prata - FACISB, Barretos, Brazil., Reis RM; Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, Brazil.; Molecular Diagnostic Laboratory, Barretos Cancer Hospital, Barretos, Brazil.; Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Braga, Portugal.; ICVS/3B's-PT Government Associate Laboratory, Braga/Guimarães, Portugal.
Jazyk:	angličtina
Zdroj:	The oncologist [Oncologist] 2024 Oct 03; Vol. 29 (10), pp. e1419-e1424.
DOI:	10.1093/oncolo/oyae129
Abstrakt:	Introduction: Lung cancer in never-smoker (LCINS) patients accounts for 20% of lung cancer cases, and its biology remains poorly understood, particularly in genetically admixed populations. We elucidated the molecular profile of driver genes in Brazilian LCINS. Methods: The mutational and gene fusion status of 119 lung adenocarcinomas from self-reported never-smoker patients, was assessed using targeted sequencing (NGS), nCounter, and immunohistochemistry. A panel of 46 ancestry-informative markers determined patients' genetic ancestry. Results: The most frequently mutated gene was EGFR (49.6%), followed by TP53 (39.5%), ALK (12.6%), ERBB2 (7.6%), KRAS (5.9%), PIK3CA (1.7%), and less than 1% alterations in RET, NTRK1, MET∆ex14, PDGFRA, and BRAF. Except for TP53 and PIK3CA, all other alterations were mutually exclusive. Genetic ancestry analysis revealed a predominance of European (71.1%), and a higher African ancestry was associated with TP53 mutations. Conclusion: Brazilian LCINS exhibited a similar molecular profile to other populations, except the increased ALK and TP53 alterations. Importantly, 73% of these patients have actionable alterations that are suitable for targeted treatments. (© The Author(s) 2024. Published by Oxford University Press.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu